Patents by Inventor Klaus Nickisch

Klaus Nickisch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HORMONAL CONTRACEPTION USING A VAGINAL RING WHICH RELEASES ESTRIOL AND TRIMEGESTONE
    Publication number: 20200383906
    Abstract: The invention relates to an intravaginal drug delivery device for hormonal contraception with prevention/reduction of intermenstrual bleeding and menopausal cycle disorders. The intravaginal drug delivery device includes estriol or a precursor of this compound and a progestogen or a precursor thereof.
    Type: Application
    Filed: June 4, 2020
    Publication date: December 10, 2020
    Inventors: Walter Elger, Klaus Nickisch
  • Cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents
    Patent number: 10738075
    Abstract: Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: August 11, 2020
    Assignee: Evestra, Inc.
    Inventors: Hareesh Nair, Bindu Santhamma, Klaus Nickisch
  • DRUG DEVICE COMBINATION FOR THE EFFECTIVE TREATMENT OF INCONTINENCE IN WOMEN
    Publication number: 20200237656
    Abstract: In embodiments described herein, an intravaginal device for treating incontinence in women includes one or more treatment modalities. The treatment modalities include: 1) incorporating an antimuscarinic agent into an intravaginal drug delivery device; 2) incorporating an estrogenic agent into an intravaginal drug delivery device, and 3) using a pessary. One or more of these modalities may be used, alone or in combination, to treat incontinence in women.
    Type: Application
    Filed: November 26, 2019
    Publication date: July 30, 2020
    Inventors: Klaus Nickisch, Karin Eggenreich, Larissa Hoffmann
  • Longer-acting progestin prodrug contraceptives
    Patent number: 10624903
    Abstract: Described herein are progestin compounds that have extended release rates and that can be used without an estrogen to produce a contraceptive state.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: April 21, 2020
    Assignee: Evestra, Inc.
    Inventors: Gulzar Ahmed, Frederick Meece, Hareesh Nair, Klaus Nickisch
  • LIF/LIFR ANTAGONIST IN ONCOLOGY AND NONMALIGNANT DISEASES
    Publication number: 20200087340
    Abstract: Described herein are methods of using compounds that inhibit leukemia inhibitory factor (LIF) and/or block of the leukemia inhibitory factor receptor for treatment of liver fibrosis, proliferation of spinal tumors, and in combination therapy with an immunotherapeutic agent.
    Type: Application
    Filed: September 13, 2019
    Publication date: March 19, 2020
    Inventors: Hareesh Nair, Bindu Santhamma, Gulzar Ahmed, Klaus Nickisch
  • HORMONAL CONTRACEPTION USING A VAGINAL RING WHICH RELEASES ESTRIOL
    Publication number: 20190328657
    Abstract: A variety of different intravaginal drug delivery devices are described for the delivery of estrogens and progestins. The release rate of estrogens and progestins can be controlled by varying the matrix material or by the application of a thin coating. The intravaginal drug delivery devices may be composed of one or more individual compartments. By controlling various physical and chemical parameters, non-zero release rates of the estrogen or progestins may be achieved.
    Type: Application
    Filed: April 26, 2019
    Publication date: October 31, 2019
    Inventors: Walter Elger, Klaus Nickisch, Ze'ev Shaked, Karin Eggenreich, Simone Eder, Andreas Witschnigg
  • ESTROGEN PRODRUGS AND METHODS OF ADMINISTERING ESTROGEN PRODRUGS
    Publication number: 20190328658
    Abstract: Disclosed herein is an intravaginal drug delivery device that includes one or more compartments, each of the one or more compartments comprising an estrogen prodrug and/or a progestin dispersed in a thermoplastic polymeric matrix.
    Type: Application
    Filed: April 26, 2019
    Publication date: October 31, 2019
    Inventors: Klaus Nickisch, Karin Eggenreich, Simone Eder, Andreas Witschnigg
  • TARGETED DELIVERY OF PROGESTINS AND ESTROGENS VIA VAGINAL RING DEVICES FOR FERTILITY CONTROL AND HRT PRODUCTS
    Publication number: 20190328656
    Abstract: A variety of different intravaginal drug delivery devices are described for the delivery of estrogens and progestins. The release rate of estrogens and progestins can be controlled by varying the matrix material or by the application of a thin coating. The intravaginal drug delivery devices may be composed of one or more individual compartments. By controlling various physical and chemical parameters, non-zero release rates of the estrogen or progestins may be achieved.
    Type: Application
    Filed: April 26, 2019
    Publication date: October 31, 2019
    Inventors: Walter Elger, Klaus Nickisch, Ze'ev Shaked, Karin Eggenreich, Simone Eder, Andreas Witschnigg
  • NOVEL CYTOTOXIC AGENTS THAT PREFERENTIALLY TARGET LEUKEMIA INHIBITORY FACTOR (LIF) FOR THE TREATMENT OF MALIGNANCIES AND AS NEW CONTRACEPTIVE AGENTS
    Publication number: 20190153018
    Abstract: Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2.
    Type: Application
    Filed: July 18, 2018
    Publication date: May 23, 2019
    Inventors: Hareesh Nair, Bindu Santhamma, Klaus Nickisch
  • Pro-drug forming compounds
    Patent number: 10273263
    Abstract: Various prodrug compounds having the general structure: Active agent—(acid)-(linker)—SO2NR1R2 are described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: April 30, 2019
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, Bindu Santhamma, Gulzar Ahmed, Frederick Meece, Walter Elger, Ralf Wyrwa, Hareesh Nair
  • LONGER-ACTING PROGESTIN PRODRUG CONTRACEPTIVES
    Publication number: 20190117670
    Abstract: Described herein are progestin compounds that have extended release rates and that can be used without an estrogen to produce a contraceptive state.
    Type: Application
    Filed: September 14, 2018
    Publication date: April 25, 2019
    Inventors: Gulzar Ahmed, Frederick Meece, Hareesh Nair, Klaus Nickisch
  • Cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents
    Patent number: 10053485
    Abstract: Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: August 21, 2018
    Assignee: Evestra, Inc.
    Inventors: Hareesh Nair, Bindu Santhamma, Klaus Nickisch
  • PROGESTERONE ANTAGONISTS
    Publication number: 20180155386
    Abstract: Described herein are compounds which either act as pure antiprogestins or as antiprogestins with partial agonistic activity and methods of treating cancer using such compounds.
    Type: Application
    Filed: December 4, 2017
    Publication date: June 7, 2018
    Inventors: Klaus Nickisch, Kesavaram Narkunan, Baishakhi Debnath, Bindu Santhamma
  • Combination of estrogens plus antiprogestins with significant partial agonistic effect as an effective treatment of menopausal symptoms and for prevention of the occurrence of breast cancer
    Patent number: 9850273
    Abstract: Described herein are compositions and methods for hormone replacement therapy that address the shortcomings of the existing methods. Described herein are pharmaceutically effective partial agonistic antiprogestins. The combined application of estrogens (such as estradiol, estriol and conjugated estrogens) and the disclosed partial agonistic antiprogestins can be used in hormone replacement therapy.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: December 26, 2017
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, Bindu Santhamma, Hareesh Nair, Walter Elger
  • PRO-DRUG FORMING COMPOUNDS
    Publication number: 20170349624
    Abstract: Various prodrug compounds having the general structure: Active agent-(acid)-(linker)-SO2NR1R2 are described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.
    Type: Application
    Filed: August 24, 2017
    Publication date: December 7, 2017
    Inventors: Klaus Nickisch, Bindu Santhamma, Gulzar Ahmed, Frederick Meece, Walter Elger, Ralf Wyrwa, Hareesh Nair
  • INTRAVAGINAL DRUG DELIVERY DEVICE
    Publication number: 20170319833
    Abstract: Described herein is an intravaginal drug delivery system. In an embodiment the intravaginal drug delivery system includes a progestin and estrogen compound, and releases the active ingredients in a fixed physiological ratio over a prolonged period of time to produce a contraceptive state in a female.
    Type: Application
    Filed: February 13, 2017
    Publication date: November 9, 2017
    Inventors: Ze'ev Shaked, Klaus Nickisch, James DiNunzio, Feng Zhang, Marcelo Omelczuk
  • Pro-drug forming compounds
    Patent number: 9745338
    Abstract: Various prodrug compounds having the general structure: Active agent-(acid)-(linker)-SO2NR1R2 are described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: August 29, 2017
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, Bindu Santhamma, Gulzar Ahmed, Frederick Meece, Walter Elger, Ralf Wyrwa, Hareesh Nair
  • NOVEL CYTOTOXIC AGENTS THAT PREFERENTIALLY TARGET LEUKEMIA INHIBITORY FACTOR (LIF) FOR THE TREATMENT OF MALIGNANCIES AND AS NEW CONTRACEPTIVE AGENTS
    Publication number: 20160279145
    Abstract: Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2.
    Type: Application
    Filed: March 22, 2016
    Publication date: September 29, 2016
    Inventors: Hareesh Nair, Bindu Santhamma, Klaus Nickisch
  • COMBINATION OF ESTROGENS PLUS ANTIPROGESTINS WITH SIGNIFICANT PARTIAL AGONISTIC EFFECT AS AN EFFECTIVE TREATMENT OF MENOPAUSAL SYMPTOMS AND FOR PREVENTION OF THE OCCURRENCE OF BREAST CANCER
    Publication number: 20160159852
    Abstract: Described herein are compositions and methods for hormone replacement therapy that address the shortcomings of the existing methods. Described herein are pharmaceutically effective partial agonistic antiprogestins. The combined application of estrogens (such as estradiol, estriol and conjugated estrogens) and the disclosed partial agonistic antiprogestins can be used in hormone replacement therapy.
    Type: Application
    Filed: December 3, 2015
    Publication date: June 9, 2016
    Inventors: Klaus Nickisch, Bindu Santhamma, Hareesh Nair, Walter Elger
  • Imidazolyl progesterone antagonists
    Patent number: 9096641
    Abstract: Described herein are imidazolyl compounds which either act as pure antiprogestins and methods of using such pure antagonists for gynecological indications and breast cancer.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: August 4, 2015
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, Walter Elger, Bindu Santhamma